Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Triple-negative Breast Cancer
100%
Aptamer
100%
Specific Binding
100%
Triple-negative Breast Cancer Cells
83%
Aptamer Probe
33%
Cell-based
16%
Therapeutic Efficacy
16%
Integrin
16%
Breast Cancer Treatment
16%
Sequence Analysis
16%
Staining Pattern
16%
Cell Membrane
16%
Surface Proteins
16%
Co-immunoprecipitation (co-IP)
16%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
16%
Targeting Ligands
16%
Target Molecule
16%
Binding Assay
16%
Tumor Tissue
16%
Targeted Therapy
16%
Targeted Cancer Therapy
16%
Carcinoma Cells
16%
Breast Cancer Xenograft
16%
Cellular Targets
16%
Target Validation
16%
Poorly Differentiated Carcinoma
16%
Peptide Sequencing
16%
Cell Staining
16%
Non-triple-negative Breast Cancer
16%
Lysed Cell
16%
Antibody Technology
16%
Medicine and Dentistry
Triple Negative Breast Cancer
100%
Aptamer
100%
Cancer Cell
50%
Biological Marker
20%
Liquid Chromatography-Mass Spectrometry
20%
Neoplasm
10%
Combination Therapy
10%
In Vitro
10%
Integrin
10%
Carcinoma Cell
10%
Binding Assay
10%
Immunoprecipitation
10%
Tumor Xenograft
10%
Cell Membrane
10%
Cancer Therapy
10%
Targeted Therapy
10%
Cell Surface Protein
10%
Tandem Mass Spectrometry
10%
Molecularly Targeted Therapy
10%
Peptide Sequence
10%
Side Effect
10%
Target Validation
10%
Immunology and Microbiology
Cancer Cell
100%
Carcinoma Cell
20%
Integrin
20%
Amino Acid Sequence
20%
Cell Membrane
20%
Xenograft
20%
Cell Surface
20%
Immunoprecipitation
20%
Liquid Chromatography Mass Spectrometry
20%
Tandem Mass Spectrometry
20%
Liquid Chromatography Tandem Mass Spectrometry
20%
In Vitro
20%
Biochemistry, Genetics and Molecular Biology
Aptamer
100%
Cancer Cell
62%
Liquid Chromatography-Mass Spectrometry
25%
Cell Membrane
12%
Peptide Sequence
12%
Cell Surface Protein
12%
Tandem Mass Spectrometry
12%
Integrin
12%
Immunoprecipitation
12%
Targeted Therapy
12%